Oncolytics Biotech Inc. (ONCY): Price and Financial Metrics
GET POWR RATINGS... FREE!
ONCY Stock Price Chart Interactive Chart >
ONCY Price/Volume Stats
|Current price||$1.12||52-week high||$3.21|
|Prev. close||$1.08||52-week low||$1.02|
|Day high||$1.15||Avg. volume||273,049|
|50-day MA||$1.38||Dividend yield||N/A|
|200-day MA||$1.74||Market Cap||64.55M|
Oncolytics Biotech Inc. (ONCY) Company Bio
Oncolytics Biotech Inc. discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.
Most Popular Stories View All
ONCY Latest News Stream
|Loading, please wait...|
ONCY Latest Social Stream
View Full ONCY Social Stream
Latest ONCY News From Around the Web
Below are the latest news stories about Oncolytics Biotech Inc that investors may wish to consider to help them evaluate ONCY as an investment opportunity.
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.
Oncolytics Biotech (NASDAQ:ONCY) said no safety concerns were seen in the three-patient pancreatic cancer group of a phase 1/2 GOBLET study evaluating pelareorep in combination with Roche's (OTCQX:RHHBY) atezolizumab. Data Safety Monitoring Board recommended the study proceed as planned. The trial, which is being managed by Germany-based academic cooperative medical oncology group...
Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the pancreatic cancer cohort of the phase 1/2 GOBLET study following evaluation by the study's Data Safety Monitoring Board (DSMB). The DSMB noted no safety concerns in these patients and recommended the study proceed as planned. The safety run-in for the trial's third-line metastatic colorectal cancer cohort remains ongoing.
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the second of three dose escalation cohorts in the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. Dosing in the trial's first dose escalation cohort is complete and no safety issues have been reported. The second dose escalation cohort is t
Oncolytics Biotech <
ONCY Price Returns